Molecule
Elinzanetant is a prescription medicine indicated for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. It is available as capsules for oral use. MedsAcross supplies Elinzanetant for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
LYNKUET is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. LYNKUET is a neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.
Source: US FDA prescribing information
LYNKUET is a neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist. Inhibition of Substance P and Neurokinin B through antagonism of NK1 and NK3 receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons can modulate neuronal activity in thermoregulation associated with hot flashes. Elinzanetant has higher affinity for human NK1 receptors (pKi values of 8.7 to 10.2) and NK3 receptors (pKi values of 8.0 to 8.8) than for human NK2 receptors (pKi values of approximately 6.0).
Source: US FDA prescribing information
The recommended dosage is 120 mg (two 60 mg capsules) orally once daily at bedtime with or without food. Swallow capsules whole. Do not cut, crush, or chew capsules. See full prescribing information for LYNKUET dosage modification due to drug interactions.
Source: US FDA prescribing information
LYNKUET is contraindicated in pregnancy. Exposure to LYNKUET may cause pregnancy loss or stillbirth when administered during pregnancy. Pregnancy.
Source: US FDA prescribing information
CNS Depressant Effect and Daytime Impairment: Advise patients about the potential for somnolence and other nervous system effects. Advise patients who experience these effects to refrain from driving or engaging in hazardous occupations or activities until the effects have resolved. Hepatic Transaminase Elevations: Perform bloodwork prior to initiation of LYNKUET to evaluate for hepatic function and injury. Do not start therapy if serum transaminase concentration is equal to or exceeds two times the upper limit of normal (ULN) or if the total bilirubin is equal to or exceeds two times the ULN. Perform follow-up evaluations of hepatic transaminase concentration 3 months after initiation. Advise patients to discontinue LYNKUET immediately in case of signs or symptoms suggesting liver injury. Risk of pregnancy loss: May cause pregnancy loss or stillbirth when administered during pregnancy.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Central Nervous System (CNS) Depressant Effect and Daytime Impairment Hepatic Transaminase Elevations Risk of Seizure The most frequently reported (≥5%) adverse reactions were headache, fatigue, dizziness and somnolence.
Source: US FDA prescribing information
Strong CYP3A4 Inhibitors and grapefruit (juice): Avoid concomitant use with LYNKUET. Moderate CYP3A4 Inhibitors: Reduce LYNKUET dosage to 60 mg once daily. 21 Strong and Moderate CYP3A4 Inducers: Avoid concomitant use with LYNKUET.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F) with excursions permitted from 15°C to 30°C (59°F to 86°F). Store the remaining capsule in the original blister card in the carton until the next dose.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Elinzanetant, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Lynkuet 60 mg capsuleOral | Bayer HealthCare Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 1 presentations of Elinzanetant and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Elinzanetant, including Lynkuet.
Yes. The US FDA first approved Elinzanetant on 24 October 2025, according to Drugs@FDA.
Yes. Elinzanetant has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Elinzanetant is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Elinzanetant is classified under ATC code G02CX07 (Elinzanetant).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.